BioNTech
NEWS
Please check out the biopharma industry’s COVID-19 stories that are trending for April 13, 2021.
BioSpace takes a look at the annual compensation for the chief executive officers of vaccine developers.
It was a busy week for clinical trial news. Here’s a look.
A current Phase III trial of the Pfizer-BioNTech COVID-19 vaccine has confirmed the protection remains high for at least six months after the second dose. In a statement, Pfizer and BioNTech reported the vaccine was 91.3% effective against the disease.
The two companies announced data from a Phase III study which showed 100% efficacy and robust antibody responses in patients ages 12 -15 who received the BNT162b2 vaccine.
Between the Moderna and Pfizer-BioNTech COVID-19 vaccines, there are two mRNA therapeutics on the market … the only two.
With the ongoing global pandemic, BioNTech and Pfizer announced that they will be boosting their manufacturing capacity of the COVID-19 vaccine to 2.5 billion for 2021.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.
There was a little bit of positive COVID-19 news to report today. Here’s a look.
JOBS
IN THE PRESS